Status:
COMPLETED
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutati...
Eligibility Criteria
Inclusion
- Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma (NHL) as follows:
- Cohort 1: Follicular lymphoma (FL)
- Cohort 2: Diffuse large B-cell lymphoma (including primary mediastinal B-cell lymphoma and transformed FL)
- Participants who have confirmed EZH2 gene mutation of tumor in central laboratory
- Participants who have measurable disease
- Participants who had previous therapy with systemic chemotherapy and/or antibody therapy and for which no standard therapy exists
- Participants who had progressive disease or did not have response (complete response or partial response) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
- Participants with Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants with life expectancy of ≥3 months from starting study drug administration
- Participants with adequate renal, liver, and bone marrow function
- Male and female participants ≥20 years of age at the time of informed consent
- Participants who has provided written consent to participate in the study
Exclusion
- Participants with prior exposure to EZH2 inhibitor
- Participants with a history or a presence of central nerves invasion
- Participants with malignant pleural effusion, cardiac effusion, or ascites retention
- Participants with allogeneic stem cell transplantation
- Participants with medical need for the continued use of potent inhibitors of Cytochrome P450 3A (CYP3A)or potent inducer of CYP3A (including St. John's wort)
- Participants with significant cardiovascular impairment
- · Participants with prolongation of corrected QT interval using Fridericia's formula to \> 480 milliseconds (msec)
- Participants with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug
- Participants with complications of hepatic cirrhosis, interstitial pneumonia or pulmonary fibrosis
- Participants with active infection requiring systemic therapy
- Women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later (for males 90 days later) from last administration of study drug
- Woman who are pregnant or breastfeeding
- Participants who were deemed as inappropriate to participate in the study by the investigator or sub-investigator
- Have any prior history of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia or myeloid malignancies, including myelodysplastic syndrome
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 17 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03456726
Start Date
April 9 2018
End Date
December 17 2021
Last Update
December 16 2022
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
1004 Eisai Trial Site
Nagoya, Aichi-ken, Japan
2
1029 Eisai Trial Site
Nagoya, Aichi-ken, Japan
3
1020 Eisai Trial Site
Ōta, Gunma, Japan
4
1007 Eisai Trial Site
Sapporo, Hokkaido, Japan